RxDoctor Payments Data

Lewis Sommerville, MD

Pulmonary Disease · Maryville, TNNPI 1548347669

Payments from drug & device makers

$13,629in general payments, 2019–2025

Across 702 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Insmed, Inc.$821
  • Grifols USA, LLC$755
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$13,52399%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,629 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$306,441
Medicare patients
285
Services billed
4,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter358$349,333
Breo ElliptaFluticasone/Vilanterol92$62,101
NucalaMepolizumab11$47,110
Stiolto RespimatTiotropium Br/Olodaterol Hcl71$38,846
SymbicortBudesonide/Formoterol Fumarate101$36,867
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$34,072
Combivent RespimatIpratropium/Albuterol Sulfate31$28,789
Advair HfaFluticasone Propion/Salmeterol53$28,121
Spiriva RespimatTiotropium Bromide17$23,927
Albuterol Sulfate HfaAlbuterol Sulfate538$22,881
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$20,964
Spiriva HandihalerTiotropium Bromide26$20,236
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$11,692
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$9,090
Arnuity ElliptaFluticasone Furoate14$6,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$1,832$486,137502 claims
Boehringer IngelheimStiolto Respimat, Combivent Respimat, Spiriva Respimat$1,119$91,562119 claims
AstraZenecaSymbicort, Breztri Aerosphere$2,246$70,939142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →